In ground­break­ing move, FDA ap­proves My­ovan­t's re­l­u­golix as the first once-a-day pill for ad­vanced prostate can­cer

My­ovant Sci­ences $MY­OV won’t be get­ting coal in their stock­ing this Christ­mas.

The Swiss biotech, for­mer­ly part of the Vivek Ra­maswamy fam­i­ly of Vants, won FDA ap­proval of its re­l­u­golix drug on Fri­day af­ter­noon for the treat­ment of ad­vanced prostate can­cer. It’s the first oral hor­mone ther­a­py ap­proved for the in­di­ca­tion, reg­u­la­tors said, and the drug will be mar­ket­ed as Or­govyx. PDU­FA ac­tion had been sched­uled for Dec. 20.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER